{"entity":{"id":"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020","kind":"paper","name":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","aka":[],"tldr":"Comparing the competing subtype schemes across trials and public data, this study found the two-type tumour-intrinsic scheme the most reproducible and built PurIST, a classifier that works on one biopsy at a time and relates to FOLFIRINOX response.","summary":"Three major subtype classification schemas were assessed against results from two clinical trials and by meta-analysis of public expression data for robustness and clinical relevance. A tumour-intrinsic two-subtype schema was most robust, replicable and clinically relevant. A single-sample classifier, PurIST, was developed by penalised logistic regression, with replicable performance across platforms and sample types including low-input biopsies; PurIST subtypes associated with prognosis and with treatment response to FOLFIRINOX.","asOf":"2026-09-24","links":[{"label":"Rashid et al., Clin Cancer Res 2020: PurIST single-sample classifier","url":"https://doi.org/10.1158/1078-0432.CCR-19-1467"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31754050/"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["rna-seq"],"targets":[],"drugs":["folfirinox"],"companies":[],"institutions":["unc-lineberger"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["clinical-cancer-research"],"dependsOn":[],"notes":[],"journal":"Clinical Cancer Research","year":2020,"doi":"10.1158/1078-0432.CCR-19-1467","pmid":"31754050","authors":"Rashid NU, Peng XL, Jin C, et al.","paperType":"methods","findings":["Two-subtype tumour-intrinsic schema most robust across datasets.","PurIST works on single low-input samples and associates with prognosis and FOLFIRINOX response."],"whatItMeans":"PurIST is the assay form of the Moffitt subtypes and the tool prospective subtype-stratified trials use.","caveats":["Retrospective association with FOLFIRINOX response.","Subtype-discordant tumours (about 12%) remain hard to call."],"changedPractice":false},"route":"/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"}],"institution":[{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/"}],"journal":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/"}]}}